Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

Abstract

We evaluated the compound imiquimod as a possible adjuvant for DNA immunization against human immunodeficiency virus (HIV). We found that gene-gun epidermal delivery of the DNA in combination with imiquimod resulted in the strongest HIV specific immune responses. The effect of imiquimod was further compared to that of recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), a known DNA vaccine adjuvant. Both adjuvants were able to enhance the immune responses induced by the HIV-1 genes alone. The delivery of an adjuvant as a topical cream rather than through injections has a clear clinical benefit. We show for the first time that imiquimod can act as an adjuvant for DNA vaccination.

Statistics

050100'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

306 Citations

Semantic Scholar estimates that this publication has 306 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Zuber2004TopicalDO, title={Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.}, author={Anne Kjerrstr{\"{o}m Zuber and Andreas Br{\aa}ve and Gunnel Engstr{\"{o}m and Bartek Zuber and Karl Ljungberg and Malin Fredriksson and Reinhold Benthin and Maria G Isaguliants and Eric Sandstr{\"{o}m and Jorma Hinkula and Britta E. Wahren}, journal={Vaccine}, year={2004}, volume={22 13-14}, pages={1791-8} }